AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C

- CHMP opinion brings AbbVie one step closer to approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis* - AbbVie's EMA label expansion is supported by 98 percent cure rate in the dedicated Phase 3b GARNET study[1] - GT1b is the most common subtype globally and accounts for 47 percent of the nine million people infected with chronic HCV in Europe[2],[3],[4] NORTH CHICAGO, Ill., Feb. 27, 2017/PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...